Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 78Melanoma 51Squamous Cell Carcinoma of Head and Neck 40Neoplasm Metastasis 30Neoplasms 27Breast Neoplasms 26Colorectal Neoplasms 23Carcinoma, Renal Cell 23Head and Neck Neoplasms 21Triple Negative Breast Neoplasms 20Carcinoma, Transitional Cell 20Stomach Neoplasms 19Ovarian Neoplasms 17Lung Neoplasms 15Uterine Cervical Neoplasms 12Esophageal Neoplasms 12Carcinoma, Hepatocellular 12Urinary Bladder Neoplasms 11Parkinson Disease 4, Autosomal Dominant Lewy Body 11Pancreatic Neoplasms 10Small Cell Lung Carcinoma 9Multiple Myeloma 9Recurrence 8Endometrial Neoplasms 8Carcinoma, Merkel Cell 8Lymphoma, Non-Hodgkin 7Lymphoma 7Skin Neoplasms 6Mesothelioma 6Hodgkin Disease 6

Interventions

pembrolizumab 1Sirolimus 1Albumin-Bound Paclitaxel 1ADI PEG20 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Advanced Solid Cancers × pembrolizumab × Clear all
NCT03254732 2022-04-27

Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers

Polaris Group

Phase 1 Terminated
33 enrolled

Advanced Solid Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡